

Press Briefing Schedule At-a-Glance

All press briefings are EMBARGOED; all on-site Press Briefings are located in McCormick Place, Lakeside Building E353a

Wednesday, May 21 Pre-Meeting Briefing on Regular Abstracts	Tuesday, May 27 Pre-Meeting Briefing on LBAs	Saturday, May 31 On-Site Briefing on Plenary Abstracts	Saturday, May 31 On-Site Briefing on LBAs
<p><b>Press Briefing Time:</b> 12:30-2:00 PM (ET) <i>Virtual event conducted via live teleconference and webinar</i></p> <p><b>1003 (Turner):</b> INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC). <b>Embargo lifts Thursday, May 22, at 5:00 PM (ET)</b></p> <p><b>8006 (Paz-Ares):</b> Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. <b>Embargo lifts Thursday, May 22, at 5:00 PM (ET)</b></p> <p><b>1014 (De Brot):</b> Use of artificial intelligence–assistance software for HER2-low and HER2-ultralow IHC interpretation training to improve diagnostic accuracy of pathologists and expand patients' eligibility for HER2-targeted treatment. <b>Embargo lifts Thursday, May 22, at 5:00 PM (ET)</b></p> <p><b>10507 (Mavromatis):</b> Glucagon-like peptide-1 receptor agonists and incidence of obesity-related cancer in adults with diabetes: A target-trial emulation study. <b>Embargo lifts Thursday, May 22, at 5:00 PM (ET)</b></p>	<p><b>Press Briefing Time:</b> 12:30-2:00 PM (ET) <i>Virtual event conducted via live teleconference and webinar</i></p> <p><b>LBA3500 (Elez):</b> First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses. <b>Embargo lifts Friday, May 30, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA8027 (Spigel):</b> An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay. <b>Embargo lifts Saturday, May 31, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA1000 (Hamilton):</b> Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study. <b>Embargo lifts Saturday, May 31, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA4002 (Shitara):</b> Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study. <b>Embargo lifts Saturday, May 31, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA109 (Tolaney):</b> Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. <b>Embargo lifts Saturday, May 31 at 7:00 AM (CT)/8:00 AM (ET)</b></p>	<p><b>Press Briefing Time:</b> 8:00-9:15 AM (CT)/9:00-10:15 AM (ET) <i>In-person and livestreamed</i></p> <p><b>LBA1 (Sinicrope):</b> Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). <b>Embargo lifts Sunday, June 1, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA2 (Bourhis):</b> NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse. <b>Embargo lifts Sunday, June 1, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA4 (Turner):</b> Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial. <b>Embargo lifts Sunday, June 1, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA5 (Janjigian):</b> Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). <b>Embargo lifts Sunday, June 1, at 7:00 AM (CT)/8:00 AM (ET)</b></p>	<p><b>Press Briefing Time:</b> 12:00-1:00 PM (CT)/1:00-2:00 PM (ET) <i>In-person and livestreamed</i></p> <p><b>LBA3509 (Char):</b> Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance). <b>Embargo lifts Sunday, June 1, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA3510 (Booth):</b> A randomized phase III trial of the impact of a structured exercise program on disease–free survival (DFS) in stage 3 or high-risk stage 2 colon cancer: Canadian Cancer Trials Group (CCTG) CO.21 (CHALLENGE). <b>Embargo lifts Sunday, June 1, at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA1008 (Tolaney):</b> Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09. <b>Embargo lifts Monday, June 2 at 7:00 AM (CT)/8:00 AM (ET)</b></p> <p><b>LBA5006 (Attard):</b> Phase 3 AMPLITUDE trial: Niraparib.3 (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes. <b>Embargo lifts Tuesday, June 3, at 7:00 AM (CT)/8:00 AM (ET)</b></p>